Merops Switch to
Peptidases

Inhibitor

Family Clan Small-molecule
inhibitor SEARCHES BLAST
MEROPS

Other
information

Literature for odanacatib (C01.036 inhibitor)

Summary Literature

(Topics flags: S Structure, I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

    2020
  1. Jaworowicz,D., Bihorel,S., Zajic,S., Stoch,S.A., Humphrey,R., McCrea,J.B. and Stone,J.A.
    Population pharmacokinetic analysis of the cathepsin K inhibitor odanacatib: insights into intrinsic and extrinsic factor effects on exposure in postmenopausal and elderly women
    J Clin Pharmacol (2020) PubMed  Europe PubMed DOI  I
  2. Seo,S.U., Woo,S.M., Kim,M.W., Lee,H.S., Kim,S.H., Kang,S.C., Lee,E.W., Min,K.J. and Kwon,T.K.
    Cathepsin K inhibition-induced mitochondrial ROS enhances sensitivity of cancer cells to anti-cancer drugs through USP27x-mediated Bim protein stabilization
    Redox Biol (2020) 30, 101422-101422. PubMed  Europe PubMed DOI  PMC  EPMC  I
    3. 2019
  3. Alberca,L.N., Chuguransky,S.R., Alvarez,C.L., Talevi,A. and Salas-Sarduy,E.
    In silico guided drug repurposing: discovery of new competitive and non-competitive inhibitors of falcipain-2
    Front Chem (2019) 7, 534-534. PubMed  Europe PubMed DOI  PMC  EPMC  I
  4. Stone,J.A., McCrea,J.B., Witter,R., Zajic,S. and Stoch,S.A.
    Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis
    Br J Clin Pharmacol (2019) 85, 1072-1083. PubMed  Europe PubMed DOI  I
    5. 2017
  5. Drake,M.T., Clarke,B.L., Oursler,M.J. and Khosla,S.
    Cathepsin K inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned
    Endocr Rev (2017) 38, 325-350. PubMed  Europe PubMed DOI  I
  6. Law,S., Andrault,P.M., Aguda,A.H., Nguyen,N.T., Kruglyak,N., Brayer,G.D. and Bromme,D.
    Identification of mouse cathepsin K structural elements that regulate the potency of odanacatib
    Biochem J (2017) 474, 851-864. PubMed  Europe PubMed DOI  S  I
  7. Yamashita,K., Iwatake,M., Okamoto,K., Yamada,S.I., Umeda,M. and Tsukuba,T.
    Cathepsin K modulates invasion, migration, and adhesion of oral squamous cell carcinomas in vitro
    Oral Dis (2017) 23, 518-525. PubMed  Europe PubMed DOI  I
    8. 2016
  8. Duong,l.T., Leung,A.T. and Langdahl,B.
    Cathepsin K inhibition: a new mechanism for the treatment of osteoporosis
    Calcif Tissue Int (2016) 98, 381-397. PubMed  Europe PubMed DOI  I
  9. Khan,M.P., Singh,A.K., Singh,A.K., Shrivastava,P., Tiwari,M.C., Nagar,G.K., Bora,H.K., Parameswaran,V., Sanyal,S., Bellare,J.R. and Chattopadhyay,N.
    Odanacatib restores trabecular bone of skeletally mature female rabbits with osteopenia but induces brittleness of cortical bone: a comparative study of the investigational drug with PTH, estrogen, and alendronate
    J Bone Miner Res (2016) 31, 615-629. PubMed  Europe PubMed DOI  I
  10. Mukherjee,K. and Chattopadhyay,N.
    Pharmacological inhibition of cathepsin K: a promising novel approach for postmenopausal osteoporosis therapy
    Biochem Pharmacol (2016) 117, 10-19. PubMed  Europe PubMed DOI  I
  11. Vermeire,J.J., Suzuki,B.M. and Caffrey,C.R.
    Odanacatib, a cathepsin K cysteine protease inhibitor, kills hookworm in vivo
    Pharmaceuticals (Basel) (2016) 9 PubMed  Europe PubMed DOI  I
    12. 2015
  12. Gamsjager,M. and Resch,H.
    [Cathepsin K antagonists: preclinical and clinical data]
    Wien Med Wochenschr (2015) 165, 65-70. PubMed  Europe PubMed DOI  I
  13. Gruber,R.
    Molecular and cellular basis of bone resorption
    Wien Med Wochenschr (2015) 165, 48-53. PubMed  Europe PubMed DOI  I
  14. Hao,L., Chen,W., McConnell,M., Zhu,Z., Li,S., Reddy,M., Eleazer,P.D., Wang,M. and Li,Y.P.
    A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease
    Infect Immun (2015) 83, 1235-1245. PubMed  Europe PubMed DOI  I
  15. Hao,L., Chen,J., Zhu,Z., Reddy,M.S., Mountz,J.D., Chen,W. and Li,Y.P.
    Odanacatib, a cathepsin K-specific inhibitor, inhibits inflammation and bone loss caused by periodontal diseases
    J Periodontol (2015) 86, 972-983. PubMed  Europe PubMed DOI  I
  16. Schultz,T.C., Valenzano,J.P., Verzella,J.L. and Umland,E.M.
    Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis
    Womens Health (Lond Engl) (2015) 11, 805-814. PubMed  Europe PubMed DOI  I
  17. Yang,W., Ko,H., Kim,H. and Kim,M.
    The effect of cathepsin K inhibitor on osteoclastic activity compared to alendronate and enamel matrix protein
    Dent Traumatol (2015) 31, 202-208. PubMed  Europe PubMed DOI  I
    18. 2014
  18. Kassahun,K., McIntosh,I., Koeplinger,K., Sun,L., Talaty,J.E., Miller,D.L., Dixon,R., Zajic,S. and Stoch,S.A.
    Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans
    Drug Metab Dispos (2014) 42, 818-827. PubMed  Europe PubMed DOI  I
  19. Nakamura,T., Shiraki,M., Fukunaga,M., Tomomitsu,T., Santora,A.C., Tsai,R., Fujimoto,G., Nakagomi,M., Tsubouchi,H., Rosenberg,E. and Uchida,S.
    Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis-a double-blind, randomized, dose-finding study
    Osteoporos Int (2014) 25, 367-376. PubMed  Europe PubMed DOI  I
  20. Pennypacker,B.L., Chen,C.M., Zheng,H., Shih,M.S., Belfast,M., Samadfam,R. and Duong,l.T.
    Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys
    J Bone Miner Res (2014) 29, 1847-1858. PubMed  Europe PubMed DOI  I
  21. Zhuo,Y., Gauthier,J.Y., Black,W.C., Percival,M.D. and Duong,L.T.
    Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible
    Bone (2014) 67, 269-280. PubMed  Europe PubMed DOI  I
    22. 2013

  22. Odanacatib, a cathepsin K inhibitor, superior to alendronate
    Bonekey Rep (2013) 2, 426-426. PubMed  Europe PubMed DOI  PMC  EPMC  I
  23. Brixen,K., Chapurlat,R., Cheung,A.M., Keaveny,T.M., Fuerst,T., Engelke,K., Recker,R., Dardzinski,B., Verbruggen,N., Ather,S., Rosenberg,E. and de Papp,A.E.
    Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial
    J Clin Endocrinol Metab (2013) 98, 571-580. PubMed  Europe PubMed DOI  I
  24. Cabal,A., Jayakar,R.Y., Sardesai,S., Phillips,E.A., Szumiloski,J., Posavec,D.J., Mathers,P.D., Savitz,A.T., Scott,B.B., Winkelmann,C.T., Motzel,S., Cook,L., Hargreaves,R., Evelhoch,J.L., Dardzinski,B.J., Hangartner,T.N., McCracken,P.J., Duong,l.T. and Williams,D.S.
    High-resolution peripheral quantitative computed tomography and finite element analysis of bone strength at the distal radius in ovariectomized adult rhesus monkey demonstrate efficacy of odanacatib and differentiation from alendronate
    Bone (2013) 56, 497-505. PubMed  Europe PubMed DOI  I
  25. Pennypacker,B.L., Oballa,R.M., Levesque,S., Kimmel,D.B. and Duong,l.T.
    Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits
    BMC Musculoskelet Disord (2013) 14, 344-344. PubMed  Europe PubMed DOI  I
  26. Stoch,S.A., Zajic,S., Stone,J.A., Miller,D.L., van Bortel,L., Lasseter,K.C., Pramanik,B., Cilissen,C., Liu,Q., Liu,L., Scott,B.B., Panebianco,D., Ding,Y., Gottesdiener,K. and Wagner,J.A.
    Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics - results from single oral dose studies in healthy volunteers
    Br J Clin Pharmacol (2013) 75, 1240-1254. PubMed  Europe PubMed DOI  I
  27. Williams,D.S., McCracken,P.J., Purcell,M., Pickarski,M., Mathers,P.D., Savitz,A.T., Szumiloski,J., Jayakar,R.Y., Somayajula,S., Krause,S., Brown,K., Winkelmann,C.T., Scott,B.B., Cook,L., Motzel,S.L., Hargreaves,R., Evelhoch,J.L., Cabal,A., Dardzinski,B.J., Hangartner,T.N. and Duong,l.T.
    Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate
    Bone (2013) 56, 489-496. PubMed  Europe PubMed DOI  I
  28. Zerbini,C.A. and McClung,M.R.
    Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence
    Ther Adv Musculoskelet Dis (2013) 5, 199-209. PubMed  Europe PubMed DOI  PMC  EPMC  I
    29. 2011
  29. Bauer,D.C.
    Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?
    J Bone Miner Res (2011) 26, 239-241. PubMed  Europe PubMed DOI  I
  30. Eisman,J.A., Bone,H.G., Hosking,D.J., McClung,M.R., Reid,I.R., Rizzoli,R., Resch,H., Verbruggen,N., Hustad,C.M., Dasilva,C., Petrovic,R., Santora,A.C., Ince,B.A. and Lombardi,A.
    Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect
    J Bone Miner Res (2011) 26, 242-251. PubMed  Europe PubMed DOI  I
  31. Isabel,E., Mellon,C., Boyd,M.J., Chauret,N., Deschenes,D., Desmarais,S., Falgueyret,J.P., Gauthier,J.Y., Khougaz,K., Lau,C.K., Leger,S., Levorse,D.A., Li,C.S., Masse,F., David Percival,M., Roy,B., Scheigetz,J., Therien,M., Truong,V.L., Wesolowski,G., Young,R.N., Zamboni,R. and Cameron Black,W.
    Difluoroethylamines as an amide isostere in inhibitors of cathepsin K
    Bioorg Med Chem Lett (2011) 21, 920-923. PubMed  Europe PubMed DOI  I
  32. Kassahun,K., Black,W.C., Nicoll-Griffith,D., McIntosh,I., Chauret,N., Day,S., Rosenberg,E. and Koeplinger,K.
    Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin K inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway
    Drug Metab Dispos (2011) 39, 1079-1087. PubMed  Europe PubMed DOI  I
  33. Kraenzlin,M.E. and Meier,C.
    Cathepsin K inhibitors in the treatment of osteoporosis
    Osteologie (2011) 20, 211-216.  I
  34. Leung,P., Pickarski,M., Zhuo,Y., Masarachia,P.J. and Duong,L.T.
    The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking
    Bone (2011) 49, 623-635. PubMed  Europe PubMed DOI  I
  35. Wijkmans,J. and Gossen,J.
    Inhibitors of cathepsin K: a patent review (2004 - 2010)
    Expert Opin Ther Pat (2011) 21, 1611-1629. PubMed  Europe PubMed DOI  I
    36. 2010
  36. Black,W.C.
    Peptidomimetic inhibitors of cathepsin K
    Curr Top Med Chem (2010) 10, 745-751. PubMed  Europe PubMed DOI  I
  37. Bone,H.G., McClung,M.R., Roux,C., Recker,R.R., Eisman,J.A., Verbruggen,N., Hustad,C.M., Dasilva,C., Santora,A.C. and Ince,B.A.
    Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density
    J Bone Miner Res (2010) 25, 937-947. PubMed  Europe PubMed DOI  I
  38. Jensen,A.B., Wynne,C., Ramirez,G., He,W., Song,Y., Berd,Y., Wang,H., Mehta,A. and Lombardi,A.
    The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial
    Clin Breast Cancer (2010) 10, 452-458. PubMed  Europe PubMed DOI  I
  39. Lewiecki,E.M.
    Targeting cathepsin K for the treatment of osteoporosis: focus on odanacatib
    Drugs Future (2010) 35, 643-649. DOI  I
    40. 2009
  40. Lewiecki,E.M.
    Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling
    IDrugs (2009) 12, 799-809. PubMed  Europe PubMed  I
  41. O'Shea,P.D., Chen,C.Y., Gauvreau,D., Gosselin,F., Hughes,G., Nadeau,C. and Volante,R.P.
    A practical enantioselective synthesis of odanacatib, a potent cathepsin K inhibitor, via triflate displacement of an alpha-trifluoromethylbenzyl triflate
    J Org Chem (2009) 74, 1605-1610. PubMed  Europe PubMed DOI  I
  42. Stoch,S.A., Zajic,S., Stone,J., Miller,D.L., Van Dyck,K., Gutierrez,M.J., De Decker,M., Liu,L., Liu,Q., Scott,B.B., Panebianco,D., Jin,B., Duong,L.T., Gottesdiener,K. and Wagner,J.A.
    Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies
    Clin Pharmacol Ther (2009) 86, 175-182. PubMed  Europe PubMed DOI  I
    43. 2008
  43. Gauthier,J.Y., Chauret,N., Cromlish,W., Desmarais,S., Duong,l.T., Falgueyret,J.P., Kimmel,D.B., Lamontagne,S., Leger,S., LeRiche,T., Li,C.S., Masse,F., McKay,D.J., Nicoll-Griffith,D.A., Oballa,R.M., Palmer,J.T., Percival,M.D., Riendeau,D., Robichaud,J., Rodan,G.A., Rodan,S.B., Seto,C., Therien,M., Truong,V.L., Venuti,M.C., Wesolowski,G., Young,R.N., Zamboni,R. and Black,W.C.
    The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K
    Bioorg Med Chem Lett (2008) 18, 923-928. PubMed  Europe PubMed DOI  I

feedback
Page created 8-September-2023

EMBL-EBI logo

© 2026 EBI
Terms of use